Choosing the right biologic for complications of inflammatory bowel disease.

Crohn’s disease Inflammatory bowel disease anti-TNF therapy biologic therapy extra-intestinal manifestations tofacitinib ulcerative colitis ustekinumab vedolizumab

Journal

Expert review of gastroenterology & hepatology
ISSN: 1747-4132
Titre abrégé: Expert Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101278199

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 1 2 2022
medline: 18 3 2022
entrez: 31 1 2022
Statut: ppublish

Résumé

Inflammatory bowel disease (IBD) is a chronic, inflammatory condition that involves the intestinal tract, and can also present with extra-intestinal manifestations (EIM). Choosing the right treatment for IBD is often nuanced and decisions can become even more complicated when a patient presents with or develops a complication of the disease. We aimed to provide an overview of the most common complications of IBD, specifically intestinal and EIM, and summarize the data regarding biologic therapy for treatment of these conditions. A comprehensive literature review was performed using PubMed and Medline databases to identify studies published in the English language relevant to the broad scope of this review. There are still significant gaps in our understanding of the pathophysiology of IBD and its treatment, especially in regards to complications of the disease. As novel therapies continue to emerge for treatment of IBD, we feel concurrent examination of their impact on intestinal complications and EIM of IBD is important and should be a priority of future research.

Identifiants

pubmed: 35094628
doi: 10.1080/17474124.2022.2036122
doi:

Substances chimiques

Biological Products 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-249

Auteurs

Shana Rakowsky (S)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA USA.

Konstantinos Papamichael (K)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA USA.

Adam S Cheifetz (AS)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH